Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors

NCT03911453 · clinicaltrials.gov ↗
EARLY_PHASE1
Phase
COMPLETED
Status
20
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University of Arizona